33524-31-1Relevant articles and documents
1-Trifluoromethylisoquinolines from α-Benzylated Tosylmethyl Isocyanide Derivatives in a Modular Approach
Wang, Lin,Studer, Armido
, p. 5701 - 5704 (2017)
The preparation of various 1-trifluoromethylisoquinolines from α-benzylated tosylmethyl isocyanide derivatives and the commercial Togni reagent using a radical cascade is reported. The starting isocyanides are readily prepared in a modular sequence from commercial tosylmethyl isocyanide via sequential double α-alkylation, and the radical reaction proceeds under mild conditions with high efficiency without any transition-metal catalyst via electron catalysis. This valuable protocol has been successfully applied to the total synthesis of CF3-mansouramycin B.
Synthesis of new iron-NHC complexes as catalysts for hydrosilylation reactions
Demir, Serpil,Goekce, Yasemin,Kaloglu, Nazan,Sortais, Jean-Baptiste,Darcel, Christophe,Oezdemir, Ismail
, p. 459 - 464 (2013)
A series of new piano-stool iron(II) complexes comprising N-heterocyclic carbene ligands [Fe(Cp)(CO)2(NHC)]I (NHC = 1,3-disubstituted imidazolidin-2-ylidene) have been synthesized and analyzed by 1H NMR, 13C NMR, IR, elemental analysis and mass spectrometric techniques. These compounds were easily prepared from the reaction of disubstituted imidazolidin-2-ylidene with [FeI(Cp)(CO)2] in toluene at room temperature. These complexes were tested in the catalytic hydrosilylation reaction of aldehydes and ketones with phenylsilane in solvent-free conditions. After a basic hydrolysis step, the corresponding alcohols were obtained in good yields. Copyright
Preparation method of 2,5-dimethoxyphenylacetic acid
-
Paragraph 0024; 0027; 0032; 0035; 0040; 0043; 0047; 0050, (2021/02/06)
The invention belongs to the technical field of drug synthesis, and particularly relates to a preparation method of 2,5-dimethoxyphenylacetic acid, wherein the method comprises the following steps: A,reacting 1,4-dimethoxybenzene in a formylation system to obtain 2,5-dimethoxybenzaldehyde; B, reacting the 2,5-dimethoxybenzaldehyde obtained in the step A with a reducing agent, extracting a reaction system, then combining organic phases, drying, concentrating under reduced pressure and distilling a crude product to obtain 2,5-dimethoxybenzyl alcohol; C, reacting the 2,5-dimethoxybenzyl alcoholobtained in the step B with a bromination reagent to obtain 2-bromomethyl-1,4-dimethoxybenzene; and D, reacting the 2-bromomethyl-1,4-dimethoxybenzene obtained in the step C with magnesium or butyl lithium and carbon dioxide in a solvent to obtain the 2,5-dimethoxyphenylacetic acid. The yield and the total yield of the 2,5-dimethoxyphenylacetic acid obtained by the method disclosed by the invention are both higher than those of 2,5-dimethoxyphenylacetic acid synthesized by a Willegerdt-Kindler method.
CD16A BINDING AGENTS AND USES THEREOF
-
Paragraph 00656, (2019/07/20)
Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.
3, 5-disubstituted hydantoin compound as well as preparation method and application thereof
-
Paragraph 0042; 0073; 0074; 0075; 0076, (2018/10/19)
The invention provides a 3, 5-disubstituted hydantoin compound as well as a preparation method and an application thereof. The structure of the compound is shown in formula I in the description. The application of the 3, 5-disubstituted hydantoin compound shown in the formula I or solvates, hydrates or salts of the compound in preparation of medicines for treating Alzheimer's disease, vascular dementia and other dementia diseases with memory impairment also belongs to the protection scope. Animal experiments prove that the compound has the effect of saving memory of animal models, has high safety, does not have mutagenicity, can stay in blood for several hours after oral administration and intravenous injection, and can enter the brain.